Trials / Completed
CompletedNCT00248144
A Study to Evaluate the Safety and Efficacy of Single Day or Single Dose Famciclovir for the Treatment of Recurrent Herpes Labialis
A Randomized, Multicenter, Double-Blinded Controlled Study to Compare the Effectiveness of a Single Dose (1500 mg) of Famciclovir, One Day (750 mg q12) of Famciclovir and Placebo in Patient-Initiated Episodic Treatment of Recurrent Herpes Labialis
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- —
- Sponsor
- Novartis · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- —
Summary
The study is designed to assess the efficacy and safety of patient-initiated therapy with famciclovir 1500 mg o.d. or 750 mg b.i.d. for one day treatment in adult men and women with recurrent herpes labialis
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Famciclovir |
Timeline
- Start date
- 2003-10-01
- Completion
- 2007-07-01
- First posted
- 2005-11-03
- Last updated
- 2007-12-10
Source: ClinicalTrials.gov record NCT00248144. Inclusion in this directory is not an endorsement.